<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>3 Healthcare Stocks We’re Skeptical Of — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">3 Healthcare Stocks We’re Skeptical Of</h2>
    <div class="badge">2025-09-08T04:33:51+00:00</div>
    <ul>
      <li>- Revenue base of $1.28 billion puts it at a disadvantage compared to larger competitors exhibiting economies of scale - Low free cash flow margin of 4% for the last five years gives it little breathing room, constrainin</li>
<li>- Customers postponed purchases of its products and services this cycle as its revenue declined by 2.9% annually over the last two years - Organic revenue growth fell short of our benchmarks over the past two years and i</li>
<li>Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently - over the past six months, the collective 1.4% gain for healthcare stocks has fallen</li>
<li>Penumbra (PEN) Market Cap: $10.98 billion Founded in 2004 to address challenging medical conditions with significant unmet needs, Penumbra (NYSE:PEN) develops and manufactures innovative medical devices for treating vasc</li>
<li>Hologic (HOLX) Market Cap: $14.85 billion As a pioneer in 3D mammography technology that has revolutionized breast cancer detection, Hologic (NASDAQ:HOLX) develops and manufactures diagnostic products, medical imaging sy</li>
<li>Danaher (DHR) Market Cap: $143.4 billion Born from a real estate investment trust that transformed into a manufacturing powerhouse, Danaher (NYSE:DHR) is a global science and technology company that provides specialized</li>
<li>Why Does PEN Worry Us?</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=3 Healthcare Stocks We’re Skeptical Of\n• - Revenue base of $1.28 billion puts it at a disadvantage compared to larger competitors exhibiting economies of scale - Low free cash flow margin of 4% for the last five years gives it little breathing room, constrainin\n• - Customers postponed purchases of its products and services this cycle as its revenue declined by 2.9% annually over the last two years - Organic revenue growth fell short of our benchmarks over the past two years and i\n• Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently - over the past six months, the collective 1.4% gain for healthcare stocks has fallen\n• Penumbra (PEN) Market Cap: $10.98 billion Founded in 2004 to address challenging medical conditions with significant unmet needs, Penumbra (NYSE:PEN) develops and manufactures innovative medical devices for treating vasc\n• Hologic (HOLX) Market Cap: $14.85 billion As a pioneer in 3D mammography technology that has revolutionized breast cancer detection, Hologic (NASDAQ:HOLX) develops and manufactures diagnostic products, medical imaging sy\n• Danaher (DHR) Market Cap: $143.4 billion Born from a real estate investment trust that transformed into a manufacturing powerhouse, Danaher (NYSE:DHR) is a global science and technology company that provides specialized\n• Why Does PEN Worry Us?" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/3-healthcare-stocks-skeptical-043351121.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>